#gwpharmaceuticalsplc

[grizzlemedia-blog]

EU Approves Epidyolex to Treat Severe Epilepsy in Children

The EU has broken new ground by approving Epidyolex in order to help doctors across Europe treat children with severe epilepsy. #marijuana #epilepsy Read the full article

[grizzlemedia-blog]

Earnings Update: Second GW Pharmaceuticals Stock Price Increase After February's Alzheimer's Trial News

GW Pharmaceuticals (NASDAQ: GWPH) has been on a tear over the past month after exceeding expectations with its Q4 results, which were released at the end of February.  

GW By the Numbers

Revenue increased 68% year on year to $6.8 million, comfortably ahead of Wall Street’s anticipated $5.4 million. Net loss of $0.20 per share was in line with its performance the previous year, and again it beat the consensus estimate. The operational highlight in Q4 was a strong launch of its flagship medicinal cannabis product, Epidiolex, in the US. It is the first CBD drug ever approved by the FDA for Dravet syndrome, a form of epilepsy, and more than 500 US doctors prescribed it in November and December 2018. That led to net sales of $4.7 million for the two-month launch period, and GW Pharmaceuticals anticipates soaring demand in the months ahead. It reported that filled prescription is up 150% in January 2019 compared to the previous month, with demand coming from major centres of excellence and local epilepsy clinics. In December, it met with the FDA about the potential for using Sativex to treat patients with Multiple Sclerosis spasticity, and it will begin a pivotal study in Q4 2019 on this. It is also undertaking a clinical trial Tuberous Sclerosis Complex, with data expected in Q2 2019. GW Pharma has a commercial footprint in place in five major European markets, and it expects the results of its European submission for Epidiolex by Q2 2019 (learn about another company capitalizing on European markets here).  

The Future of Pharmaceuticals is Bright for GW

The firm is set to enjoy continued momentum in 2019 as there is an unmet medical need to treat Dravet syndrome. It is also diversifying by launching trials into treating different conditions, and investors are impressed. GW Pharmaceuticals Medicinal Cannabis Drug Trials

Source: GW Pharmaceuticals Earnings Presentation Tekla Capital Management LLC raised its holdings in GW by 45.3% during Q4, while Resources Investment Advisors Inc. and Horrell Capital Management Inc. both lifted their shares. NumerixS Investment Technologies Inc and Oppenheimer Asset Management Inc. both purchased new positions in the firm. The share price was $97.39 on December 31, 2019, and it increased to $152.89 by February 26. It then saw a sharp increase to $173.99 after its Q4 results were announced, and it has now settled at $166.57 this week. It has a strong balance sheet, with plenty of growth potential, so it is likely to remain a popular stock among investors in the year ahead.  

Recall - Not the Only Recent Stock Price Spike For GW

GW Pharmaceuticals saw its share price increase in mid-February after Alzheimer’s Research UK announced a cannabis trial with the British firm. Cambridge-based GW Pharmaceuticals produces a cannabis mouth spray called Sativex that contains equal amounts of THC and CBD. It became the first cannabis-based medicine to be licensed in the UK and it is used to treat symptoms of multiple sclerosis, including spasticity, pain, tremors, and sleep disturbance. Now the respected charity Alzheimer’s Research UK has decided to fund a pioneering clinical trial at King’s College in London to discover the efficacy of Sativex in treating dementia sufferers. It said that around half of the 850,000 Brits living with Alzheimer's will experience agitation or aggression, making it one of the most challenging symptoms of the illness. It hopes that cannabis can negate this. It is devoting around £300,000 ($384,000) to the trial, which will see a study team recruit volunteers aged between 55 and 90 who suffer from dementia and experience symptoms of aggression or agitation. They will take Sativex for four weeks and, if their symptoms improve, they will perform a much larger clinical trial. Right now only MS patients can be prescribed Sativex, but Alzheimer’s Research UK will aim to change that if the spray proves to be effective. The researchers need to assess how practical it is to use a mouth spray if a patient is displaying extreme aggression. But chief scientific officer Dr. David Reynolds said no new dementia treatments have emerged in the past 15 years and that it is imperative for the medical community to test novel treatment methods in rigorous clinical trials. GW Pharmaceutical’s stock price increased to $1520.50 at the close of trading on February 15th. Cannabis is legal for medicinal purposes in the UK, but it has not taken off to the extent seen in countries like Germany. That is due to the strictness of guidelines that doctors must adhere to, but the landscape is starting to change and this trial could help unlock the industry. Read the full article

[grizzlemedia-blog]

GW Pharmaceuticals Shares Increase After Alzheimer's Trial Revealed

GW Pharmaceuticals (NASDAQ: GWPH) saw its share price increase this morning after Alzheimer’s Research UK announced a cannabis trial with the British firm. #marijuanastocks #potstocks $GWPH Read the full article

[grizzlemedia-blog]

Epidiolex Maker GW Pharmaceuticals Raises $345 Million Through Share Sale

GW Pharmaceuticals (NASDAQ: GWPH), maker of the epilepsy treatment Epidiolex, has raised $345 million to fund an expansion drive. #marijuanastocks #potstocks Read the full article

[grizzlemedia-blog]

Marijuana News - Weekly Investor Roundup (August 11th)

Germany Will Disappoint Cannabis Investors

The German government is making sure the domestic cannabis market develops slowly and is taking unusual steps in the financial markets to make sure the industry isn't able to put on too much political pressure. German demand will likely disappoint licensed producers and investors in the next 5 years.   

Read more»

Colorado and Oregon Show the Do's and Don'ts of Cannabis Regulation

In 2017 Colorado grew 340,000 kg of legal marijuana and sold 90% of it to consumers. The black market is estimated to make up 25% of sales. In contrast, Oregon produces 750,000 kg annually and only 30% is ever sold legally, meaning the rest is destroyed or sold on the black market, many times across state lines. What explains this stark difference? It all comes down to regulations.

Read more»

Lagunitas Opens Infused Beverage Floodgates

On July 30, Heineken, through its Lagunitas beer brand, launched the first mainstream cannabis infused beer, Hi-Fi Hops and it's flying off the shelves in California dispensaries. Heineken may be the first, but with Molson Coors recently entering the cannabis drinks business it’s only a matter of time until your local dispensary is fully stocked with an assortment of infused and cannabis brewed beer.

Source: Lagunitas Read more»

First Government Approved Drug Therapy Will Cost $35k

Epidiolex, the maker of the first government-approved epilepsy therapy derived from cannabis, will charge $35,000 a year for patients to take the drug, a price much higher than buying cannabis oil directly from a licensed producer. Epidiolex is the first US-approved pharmaceutical drug made from cannabis, but will most definitely not be the last.

http://www.gwpharm.com/ Read more»

Germans Can Now Buy Medical Marijuana Stocks

Clearstream, a major clearing broker for the German stock exchange, is no longer barring German investors from buying all cannabis companies. Companies involved in medical marijuana can now be purchased. Approved Securities LINK Restricted Securities LINK

Source: World Atlas Read more»

Cannabis Fundraising Hits New Record So Far In 2018 

The $4.3 billion raised so far this year already surpasses the $3.5 billion raised in all of 2017. Growers and retailers represent 60% of money raised. Forecasts expect cannabis biotech and infused product companies to be the new fundraising theme in the next 12 months.

Read more»

Marijuana Stock Performance for the Week

Marijuana stocks had a slight bounce back this week up 1.2%, but are still up only 2.5% from the yearly low they reached on July 26. Cannabis stocks are still looking for a new catalyst to raise investor expectations, but legalization alone is currently not enough. Dilution earlier in the year from M&A and capital raises is putting some serious pressure on the stock prices of some larger producers, coupled with a risk off attitude among cannabis investors. Market Outlook Even with all of the positive momentum on legalization in Canada, stocks are down 7% since the recent bottom in April. Retail investors are still waiting for a rebound in stocks leading up to legalization, which could happen for a few weeks just before the October 17 legalization date with some follow through into the end of the year due to a shortage of product, but it's looking like this is going to be a long summer of lacklustre performance.

Read more»   READ LEGALIZATION IS INEVITABLE IN AMERICA  FOR AN IN-DEPTH REPORT ON WHY FEDERAL LEGALIZATION COULD BE A REALITY IN LESS THAN 3 YEARS Read the full article

[grizzlemedia-blog]

Marijuana News: Weekly Investor Roundup (June 23rd)

Marijuana News: Cannabis legalization date confirmed. First FDA approval of a marijuana drug may be days away, Jamaica jumping into growing game and more. #marijuananews  Read the full article

[grizzlemedia-blog]

Marijuana News: Weekly Investor Roundup (June 15th)

Weekly Marijuana News Roundup: Cannabis legalization likely slips to late September. German medical patient numbers revealed, how to invest in the pharmaceutical grade marijuana trend and more.  Read the full article

[grizzlemedia-blog]

Investing in Medical Marijuana Stocks the Right Way

The argument for marijuana as a legitimate medicine is rapidly gaining momentum as more and more clinical studies are released. The illegal nature of marijuana has made it hard for doctors and researchers to conduct clinical trials and source product to experiment on, but once legalization arrives in Canada later this year, we think the medical data backing up the efficacy of marijuana as an epilepsy medicine will explode. The positive effect medical marijuana has on epilepsy patients' quality of life is a feel good story for sure, but how big is the market for epilepsy medicine really? We aim to find out if marijuana's rise as the epilepsy cure is a big money opportunity for licensed producers or another bull market mirage. Read the full article